ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Tea drinkers have lower glaucoma risk

Soy, cruciferous vegetables could help lower breast cancer treatment side effects

The Long-Term Benefits of Drinking Oolong Tea

Wonderful White Tea: A Drink Fit for an Emperor

Why You Should Try This Sweet-Smelling and Health-Boosting Essential Oil

Basic Aromatherapy to Help Balance and Calm

Arnica: This Powerful Herb Promotes Various Kinds of Healing

Chamomile Tea: Why This Ancient Therapeutic Drink Still Stands Out Today

Get ‘Hooked’ on Cat’s Claw: The Many Benefits of This Amazonian Herb

Try Apple Cider Vinegar and Black Cumin Oil as Your Go-To Salad Dressing

 
Print Page
Email Article

UAMS Reports Bone Loss From Oral Diabetes Drug

  [ 30 votes ]   [ Discuss This Article ]
www.ProHealth.com • October 9, 2003


LITTLE ROCK, Ark., Oct. 8 /PRNewswire/ -- Scientists at the University of Arkansas for Medical Sciences (UAMS) report in the journal Endocrinology that a widely used oral drug for type 2 diabetes may pose a significant risk of bone loss.

The researchers report that in a laboratory study the anti-diabetic compound rosiglitazone (known as Avandia), caused a significant decrease in total body bone mineral density, suggesting that Avandia therapy may pose a significant risk of adverse skeletal effects in humans.

"Avandia is an FDA-approved and clinically successful treatment for type 2 diabetes. Our findings suggest that doctors should watch the skeletons of patients who use this drug, especially older patients, because their patients may be at increased risk of bone loss over time," said lead researcher Beata Lecka-Czernik, Ph.D., a molecular and cell biologist.

An estimated 16 million Americans have type 2 diabetes, which results from insulin resistance, a condition in which the body does not properly use insulin, along with relative insulin deficiency. The disease typically develops in people over the age of 40. Rosiglitazone, a very effective anti-diabetic agent that reduces insulin resistance, has had federal approval since 1999.

The National Institute on Aging funded the research at UAMS with a five-year, $925,000 grant. Physiologists and endocrinologists Larry J. Suva, Ph.D., and Dana Gaddy, Ph.D., are co-investigators. Lecka-Czernik is a member of the Donald W. Reynolds Department of Geriatrics and Suva and Gaddy are members of the faculty of the Departments of Orthopaedic Surgery and Physiology and Biophysics, all in the UAMS College of Medicine. All three researchers are members of the Arkansas Cancer Research Center at UAMS. S. O. Rzonca and D. C. Montague, research assistants who conducted the experiment and technical analyses, are co-authors of the article in Endocrinology.

The UAMS scientists used micro-computed tomography to analyze the bones of healthy mice that received doses of rosiglitazone over seven weeks. The doses that mice received were the same doses mice received in earlier studies that demonstrated the compound's effectiveness for type 2 diabetes. The researchers next plan to test the effects of the drug on mice and rats with diabetes. Lecka-Czernik also has a grant for the follow-up study of $300,000
for three years from the American Diabetes Association.

A gift of $288,000 from the Roy and Christine Sturgis Charitable Trust in 2002 enabled UAMS to purchase the sophisticated bone analysis equipment used in the study.

The journal Endocrinology is published by The Endocrine Society. UAMS is the leading biomedical research institution in Arkansas and the home of the Donald W. Reynolds Center on Aging as well as the Donald W. Reynolds Department of Geriatrics.

SOURCE: University of Arkansas for Medical Sciences
Web Site: http://www.uams.edu



Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg Optimized Curcumin Longvida® Mitochondria Ignite™ with NT Factor®


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get Energized with Malic Acid & Magnesium
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health

Natural Remedies

Guarding Against the Dangers of Vitamin D Deficiency Guarding Against the Dangers of Vitamin D Deficiency
How I Found My Long-Lost Energy How I Found My Long-Lost Energy
The Fibromyalgia and Glutathione Link The Fibromyalgia and Glutathione Link
Stop Bacteria With Nature's Antibiotics Stop Bacteria With Nature's Antibiotics
Block Acid Reflux to Prevent Esophageal Problems! Block Acid Reflux to Prevent Esophageal Problems!

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2018 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map